Search results
1 day ago · Pratheeba Vimalnath. University of Exeter Business School, University of Exeter, Exeter, UK. Search for more papers by this author
4 days ago · 31st July 2024. Number of awards: 1. Value: This 4-year studentship is funded through a Cancer Research UK Programme Grant (CanDetect) and comes with a tax-free stipend of £19,237 and will cover Home tuition feesplus a contribution towards research and training costs. Students who pay internation. Duration of award:
4 days ago · About Alastair. Alastair co-founded a digital marketing agency, Optix Solutions, when he was just 19 at Exeter University. In the last 25 years that company has become one of the leading agencies in the country, employing around 25 people and working with the likes of the Met Office, Exeter University, Pearson Languages the NHS & London Business School.
5 days ago · Our Digital Summer Showcase 2024. Co-creation with our users is at the heart of the University’s 2030 Digital Strategy – not only are our products and services user-led, but the Strategy was developed based on months of user research and insight. We want to ensure that the Digital team are supporting the goals of the whole University ...
1 day ago · Previous observational studies have indicated that social influences, such as arising from herding-like behaviour, can contribute to medical errors. In this study, we experimentally examined whether general practitioners (GPs) would follow incorrect prescription recommendations from fellow GP or specialists. To investigate this, we conducted an online survey with 475 GPs practicing in England ...
2 days ago · The MEDMI (Medical and Environmental Data-a Mash-up Infrastructure) Partnership brings together leading U.K. organizations and researchers in climate, weather, environment, and human health (University of Exeter, U.K. MET Office, Public Health England; and the London School of Hygiene and Tropical Medicine).
10 hours ago · Cytoreductive treatments for patients diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental survival benefits over systemic therapy, but these may lead to added toxicity and morbidity.
